Mirum Pharmaceuticals, Inc.

NASDAQ:MIRM

50.21 (USD) • At close February 4, 2025
Bedrijfsnaam Mirum Pharmaceuticals, Inc.
Symbool MIRM
Munteenheid USD
Prijs 50.21
Beurswaarde 2,410,310,966
Dividendpercentage 0%
52-weken bereik 23.14 - 50.34
Industrie Biotechnology
Sector Healthcare
CEO Mr. Christopher Peetz
Website https://www.mirumpharma.com

An error occurred while fetching data.

Over Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome

Vergelijkbare Aandelen

Sana Biotechnology, Inc. logo

Sana Biotechnology, Inc.

SANA

3.17 USD

Enanta Pharmaceuticals, Inc. logo

Enanta Pharmaceuticals, Inc.

ENTA

5.12 USD

Syndax Pharmaceuticals, Inc. logo

Syndax Pharmaceuticals, Inc.

SNDX

14.41 USD

Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc.

KROS

11 USD

Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc.

ACRS

2.51 USD

REGENXBIO Inc. logo

REGENXBIO Inc.

RGNX

8.43 USD

National Research Corporation logo

National Research Corporation

NRC

16.28 USD

Kura Oncology, Inc. logo

Kura Oncology, Inc.

KURA

8.89 USD

FibroGen, Inc. logo

FibroGen, Inc.

FGEN

0.463 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)